Download PDF
Semin Respir Crit Care Med 2020; 41(03): 435-446
DOI: 10.1055/s-0039-1700566
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Small Cell Lung Cancer: Advances in Diagnosis and Management

Ayushi F. Chauhan
1   Division of Medical Oncology, Georgetown University, Washington, District of Columbia, Washington, DC
,
Stephen V. Liu
1   Division of Medical Oncology, Georgetown University, Washington, District of Columbia, Washington, DC
› Author Affiliations
Further Information

Publication History

Publication Date:
25 May 2020 (online)

    Permissions and Reprints

Abstract

Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and management typically involves chemotherapy, delivered with thoracic radiation in early-stage disease. Platinum-based chemotherapy is initially very effective, inducing rapid and often deep responses. These responses, though, are transient, and upon relapse, SCLC is highly refractory to therapy. Immunotherapy has shown promise in delivering meaningful, durable responses and the addition of immunotherapy to first-line chemotherapy has led to the first improvements in survival in decades. Still, the disease remains difficult to manage. Incorporating radiation therapy at specific points in patient management may improve disease control. The development of predictive biomarkers and novel targeted therapies will hopefully improve options for patients in the near future. This review focuses on the current standards of care and future directions.

Keywords

small cell lung cancer - immunotherapy - chemotherapy - targeted therapy - review
 

  • References

  • 1 Travis WD, Brambilla E, Burke A. , et al, eds. The concept of pulmonary neuroendocrine tumours. In: Pathology & Genetics: Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 2004: 19
    Google Scholar
  • 2 Govindan R, Page N, Morgensztern D. , et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24 (28) 4539-4544
    CrossrefPubMedGoogle Scholar
  • 3 Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012; 75 (03) 280-284
    CrossrefPubMedGoogle Scholar
  • 4 Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012; 25 (Suppl. 01) S18-S30
    PubMedGoogle Scholar
  • 5 Nicholson SA, Beasley MB, Brambilla E. , et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002; 26 (09) 1184-1197
    CrossrefPubMedGoogle Scholar
  • 6 Guinee Jr DG, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994; 102 (04) 406-414
    CrossrefPubMedGoogle Scholar
  • 7 Aupérin A, Arriagada R, Pignon J-P. , et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341 (07) 476-484
    CrossrefPubMedGoogle Scholar
  • 8 Seute T, Leffers P, ten Velde GPM, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 2008; 112 (08) 1827-1834
    CrossrefPubMedGoogle Scholar
  • 9 Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer?. Clin Lung Cancer 2008; 9 (01) 30-34
    CrossrefPubMedGoogle Scholar
  • 10 Brink I, Schumacher T, Mix M. , et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31 (12) 1614-1620
    CrossrefPubMedGoogle Scholar
  • 11 van Loon J, De Ruysscher D, Wanders R. , et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77 (02) 329-336
    CrossrefPubMedGoogle Scholar
  • 12 Lee YJ, Cho A, Cho BC. , et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009; 15 (07) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 13 Stahel RA, Ginsberg R, Havemann K. , et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5 (4–6): 119-126
    CrossrefPubMedGoogle Scholar
  • 14 Micke P, Faldum A, Metz T. , et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?. Lung Cancer 2002; 37 (03) 271-276
    CrossrefPubMedGoogle Scholar
  • 15 Goldstraw P, Chansky K, Crowley J. , et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11 (01) 39-51
    CrossrefPubMedGoogle Scholar
  • 16 Shepherd FA, Crowley J, Van Houtte P. , et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2 (12) 1067-1077
    CrossrefPubMedGoogle Scholar
  • 17 Ignatius Ou S-H, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 2009; 4 (03) 300-310
    CrossrefPubMedGoogle Scholar
  • 18 Moreno AC, Lin SH. The optimal treatment approaches for stage I small cell lung cancer. Transl Lung Cancer Res 2019; 8 (01) 88-96
    CrossrefPubMedGoogle Scholar
  • 19 Wakeam E, Acuna SA, Leighl NB. , et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer 2017; 109: 78-88
    CrossrefPubMedGoogle Scholar
  • 20 Rudin CM, Giaccone G, Ismaila N. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Oncol Pract 2016; 12 (01) 83-86
    CrossrefPubMedGoogle Scholar
  • 21 Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e400S-e419S
    CrossrefPubMedGoogle Scholar
  • 22 Stinchcombe TE. Current treatments for surgically resectable, limited-stage, and extensive-stage small cell lung cancer. Oncologist 2017; 22 (12) 1510-1517
    CrossrefPubMedGoogle Scholar
  • 23 Vallières E, Shepherd FA, Crowley J. , et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4 (09) 1049-1059
    CrossrefPubMedGoogle Scholar
  • 24 Thomas DC, Arnold BN, Rosen JE. , et al. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2017; 103: 75-81
    CrossrefPubMedGoogle Scholar
  • 25 Fukuoka M, Furuse K, Saijo N. , et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83 (12) 855-861
    CrossrefPubMedGoogle Scholar
  • 26 Kim E, Biswas T, Bakaki P, Dowlati A, Sharma N, Machtay M. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. Pract Radiat Oncol 2016; 6 (05) e163-e169
    CrossrefPubMedGoogle Scholar
  • 27 Pignon J-P, Arriagada R, Ihde DC. , et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327 (23) 1618-1624
    CrossrefPubMedGoogle Scholar
  • 28 Takada M, Fukuoka M, Kawahara M. , et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20 (14) 3054-3060
    CrossrefPubMedGoogle Scholar
  • 29 Fried DB, Morris DE, Poole C. , et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22 (23) 4837-4845
    CrossrefPubMedGoogle Scholar
  • 30 Turrisi III AT, Kim K, Blum R. , et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340 (04) 265-271
    CrossrefPubMedGoogle Scholar
  • 31 Faivre-Finn C, Snee M, Ashcroft L. , et al; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18 (08) 1116-1125
    CrossrefPubMedGoogle Scholar
  • 32 Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; 106 (6, Suppl): 320S-323S
    CrossrefPubMedGoogle Scholar
  • 33 Kristjansen PE, Kristensen CA. The role of prophylactic cranial irradiation in the management of small cell lung cancer. Cancer Treat Rev 1993; 19 (01) 3-16
    PubMedGoogle Scholar
  • 34 Pelayo Alvarez M, Westeel V, Cortés-Jofré M, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2013; (11) CD001990
    PubMedGoogle Scholar
  • 35 Giordano KF, Jatoi A, Adjei AA. , et al. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer 2005; 49 (02) 209-215
    CrossrefPubMedGoogle Scholar
  • 36 Rossi A, Di Maio M, Chiodini P. , et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30 (14) 1692-1698
    CrossrefPubMedGoogle Scholar
  • 37 Noda K, Nishiwaki Y, Kawahara M. , et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346 (02) 85-91
    CrossrefPubMedGoogle Scholar
  • 38 Schmittel A, Fischer von Weikersthal L, Sebastian M. , et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006; 17 (04) 663-667
    CrossrefPubMedGoogle Scholar
  • 39 Hanna N, Bunn Jr PA, Langer C. , et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24 (13) 2038-2043
    CrossrefPubMedGoogle Scholar
  • 40 Rizvi NA, Hellmann MD, Snyder A. , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348 (6230): 124-128
    CrossrefPubMedGoogle Scholar
  • 41 Reck M, Bondarenko I, Luft A. , et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24 (01) 75-83
    CrossrefPubMedGoogle Scholar
  • 42 Reck M, Luft A, Szczesna A. , et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 2016; 34 (31) 3740-3748
    CrossrefPubMedGoogle Scholar
  • 43 Horn L, Mansfield AS, Szczęsna A. , et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379 (23) 2220-2229
    CrossrefPubMedGoogle Scholar
  • 44 Slotman B, Faivre-Finn C, Kramer G. , et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357 (07) 664-672
    CrossrefPubMedGoogle Scholar
  • 45 Takahashi T, Yamanaka T, Seto T. , et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18 (05) 663-671
    CrossrefPubMedGoogle Scholar
  • 46 Gondi V, Paulus R, Bruner DW. , et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys 2013; 86 (04) 656-664
    CrossrefPubMedGoogle Scholar
  • 47 Jeremic B, Shibamoto Y, Nikolic N. , et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17 (07) 2092-2099
    CrossrefPubMedGoogle Scholar
  • 48 Yee D, Butts C, Reiman A. , et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol 2012; 102 (02) 234-238
    CrossrefPubMedGoogle Scholar
  • 49 Slotman BJ, van Tinteren H, Praag JO. , et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385 (9962): 36-42
    CrossrefPubMedGoogle Scholar
  • 50 Rathod S, Jeremic B, Dubey A. , et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 2019; 110: 110-119
    CrossrefPubMedGoogle Scholar
  • 51 Gore EM, Hu C, Sun AY. , et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol 2017; 12 (10) 1561-1570
    CrossrefPubMedGoogle Scholar
  • 52 Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991; 99 (06) 1425-1432
    CrossrefPubMedGoogle Scholar
  • 53 Cheng S, Evans WK, Stys-Norman D, Shepherd FA. ; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007; 2 (04) 348-354
    CrossrefPubMedGoogle Scholar
  • 54 Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur J Cancer 2014; 50 (13) 2211-2218
    CrossrefPubMedGoogle Scholar
  • 55 Ardizzoni A, Hansen H, Dombernowsky P. , et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15 (05) 2090-2096
    CrossrefPubMedGoogle Scholar
  • 56 O'Brien MER, Ciuleanu T-E, Tsekov H. , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24 (34) 5441-5447
    CrossrefPubMedGoogle Scholar
  • 57 Treat J, Huang CH, Lane SR, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004; 9 (02) 173-181
    CrossrefPubMedGoogle Scholar
  • 58 von Pawel J, Schiller JH, Shepherd FA. , et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17 (02) 658-667
    CrossrefPubMedGoogle Scholar
  • 59 Armstrong SA, Liu SV. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. Adv Ther 2019; 36 (08) 1826-1832
    CrossrefPubMedGoogle Scholar
  • 60 Eckardt JR, von Pawel J, Pujol J-L. , et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25 (15) 2086-2092
    CrossrefPubMedGoogle Scholar
  • 61 Masters GA, Declerck L, Blanke C. , et al; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003; 21 (08) 1550-1555
    CrossrefPubMedGoogle Scholar
  • 62 van der Lee I, Smit EF, van Putten JW. , et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001; 12 (04) 557-561
    CrossrefPubMedGoogle Scholar
  • 63 Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA. Phase II trial of vinflunine in relapsed small cell lung cancer. J Thorac Oncol 2010; 5 (06) 874-878
    CrossrefPubMedGoogle Scholar
  • 64 Furuse K, Kubota K, Kawahara M. , et al; Japan Lung Cancer Vinorelbine Study Group. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996; 53 (02) 169-172
    CrossrefPubMedGoogle Scholar
  • 65 Pietanza MC, Kadota K, Huberman K. , et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012; 18 (04) 1138-1145
    CrossrefPubMedGoogle Scholar
  • 66 Zauderer MG, Drilon A, Kadota K. , et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014; 86 (02) 237-240
    CrossrefPubMedGoogle Scholar
  • 67 Evans TL, Cho BC, Udud K. , et al. Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy. J Thorac Oncol 2015; 10 (08) 1221-1228
    CrossrefPubMedGoogle Scholar
  • 68 Ettinger DS, Jotte R, Lorigan P. , et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010; 28 (15) 2598-2603
    CrossrefPubMedGoogle Scholar
  • 69 von Pawel J, Jotte R, Spigel DR. , et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32 (35) 4012-4019
    CrossrefPubMedGoogle Scholar
  • 70 Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21 (01) 45-48
    PubMedGoogle Scholar
  • 71 Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987; 23 (09) 1409-1411
    CrossrefPubMedGoogle Scholar
  • 72 Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23 (11) 1697-1699
    CrossrefPubMedGoogle Scholar
  • 73 Batist G, Ihde DC, Zabell A. , et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med 1983; 98 (04) 472-474
    PubMedGoogle Scholar
  • 74 Garassino MC, Torri V, Michetti G. , et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 2011; 72 (03) 378-383
    CrossrefPubMedGoogle Scholar
  • 75 Korkmaz T, Seber S, Kefeli U. , et al. Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis. Clin Transl Oncol 2013; 15 (07) 535-540
    CrossrefPubMedGoogle Scholar
  • 76 Naito Y, Yamada K, Imamura Y. , et al. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer. Med Oncol 2018; 35 (05) 61
    CrossrefPubMedGoogle Scholar
  • 77 Genestreti G, Tiseo M, Kenmotsu H. , et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin Lung Cancer 2015; 16 (06) e223-e228
    CrossrefPubMedGoogle Scholar
  • 78 Goto K, Ohe Y, Shibata T. , et al; JCOG0605 investigators. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17 (08) 1147-1157
    CrossrefPubMedGoogle Scholar
  • 79 Masuda N, Fukuoka M, Kusunoki Y. , et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10 (08) 1225-1229
    CrossrefPubMedGoogle Scholar
  • 80 Morise M, Niho S, Umemura S. , et al. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Jpn J Clin Oncol 2014; 44 (09) 846-851
    CrossrefPubMedGoogle Scholar
  • 81 Kondo R, Watanabe S, Shoji S. , et al. A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology 2018; 94 (04) 223-232
    CrossrefPubMedGoogle Scholar
  • 82 Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990; 8 (10) 1613-1617
    CrossrefPubMedGoogle Scholar
  • 83 Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77 (02) 347-351
    CrossrefPubMedGoogle Scholar
  • 84 Yamamoto N, Tsurutani J, Yoshimura N. , et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006; 26 (1B): 777-781
    PubMedGoogle Scholar
  • 85 Smyth JF, Smith IE, Sessa C. , et al; The Early Clinical Trials Group of the EORTC. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A (08) 1058-1060
    PubMedGoogle Scholar
  • 86 Paz-Ares LG, Trigo Perez JM, Besse B. , et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial. J Clin Oncol 2019; 37 (Suppl): 8506
    CrossrefPubMedGoogle Scholar
  • 87 Ott PA, Elez E, Hiret S. , et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 2017; 35 (34) 3823-3829
    CrossrefPubMedGoogle Scholar
  • 88 Chung HC, Lopez-Martin JA, Kao SC-H. , et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol 2018; 36 (15_suppl): 8506
    CrossrefPubMedGoogle Scholar
  • 89 Chung HC, Piha-Paul SA, Lopez-Martin J. , et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): results from the KEYNOTE-028 and KEYNOTE-158 studies. In: Proc 110th Annu Meet Am Assoc Cancer Res; 2019 Mar 29–April 3, 2019; Atlanta, GA
    PubMedGoogle Scholar
  • 90 Ready NE, Ott PA, Hellman MD. , et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032. Randomized Cohort 2019; 15 (03) 426-435
    PubMedGoogle Scholar
  • 91 Ready N, Farago AF, de Braud F. , et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 2019; 14 (02) 237-244
    CrossrefPubMedGoogle Scholar
  • 92 Steffens C-C, Elender C, Hutzschenreuter U. , et al; TLK-Group (Tumour Registry Lung Cancer). Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - results from the prospective German TLK cohort study. Lung Cancer 2019; 130: 216-225
    CrossrefPubMedGoogle Scholar
  • 93 Reck M, Vicente D, Ciuleanu T. , et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331. Ann Oncol 2018; 29 (Suppl. 10) mdy511.004
    PubMedGoogle Scholar
  • 94 Pujol J-L, Greillier L, Audigier-Valette C. , et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. J Thorac Oncol 2019; 14 (05) 903-913
    CrossrefPubMedGoogle Scholar
  • 95 Gadgeel SM, Pennell NA, Fidler MJ. , et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol 2018; 13 (09) 1393-1399
    CrossrefPubMedGoogle Scholar
  • 96 Owonikoko TK, Kim HR, Govindan R. , et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, rando. Ann Oncol 2019; 30 (Suppl. 02) ii77-ii80
    PubMedGoogle Scholar
  • 97 Hellmann MD, Callahan MK, Awad MM. , et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2018; 33 (05) 853.e4-861.e4
    PubMedGoogle Scholar
  • 98 Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clin Cancer Res 2015; 21 (10) 2213-2220
    CrossrefPubMedGoogle Scholar
  • 99 Brown NA, Aisner DL, Oxnard GR. Precision medicine in non-small cell lung cancer: current standards in pathology and biomarker interpretation. Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet 2018; 38 (38) 708-715
    PubMedGoogle Scholar
  • 100 Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003; 21 (03) 229-239
    CrossrefPubMedGoogle Scholar
  • 101 Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev 2015; 29 (14) 1447-1462
    CrossrefPubMedGoogle Scholar
  • 102 George J, Lim JS, Jang SJ. , et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524 (7563): 47-53
    CrossrefPubMedGoogle Scholar
  • 103 Krystal G, Birrer M, Way J. , et al. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol 1988; 8 (08) 3373-3381
    CrossrefPubMedGoogle Scholar
  • 104 Umemura S, Mimaki S, Makinoshima H. , et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 2014; 9 (09) 1324-1331
    CrossrefPubMedGoogle Scholar
  • 105 Peifer M, Fernández-Cuesta L, Sos ML. , et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44 (10) 1104-1110
    CrossrefPubMedGoogle Scholar
  • 106 Rudin CM, Durinck S, Stawiski EW. , et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44 (10) 1111-1116
    CrossrefPubMedGoogle Scholar
  • 107 Tarhini A, Kotsakis A, Gooding W. , et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010; 16 (23) 5900-5907
    CrossrefPubMedGoogle Scholar
  • 108 Pandya KJ, Dahlberg S, Hidalgo M. , et al; Eastern Cooperative Oncology Group (E1500). A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2 (11) 1036-1041
    CrossrefPubMedGoogle Scholar
  • 109 Koinis F, Agelaki S, Karavassilis V. , et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer 2017; 117 (01) 8-14
    CrossrefPubMedGoogle Scholar
  • 110 Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017; 14 (09) 549-561
    CrossrefPubMedGoogle Scholar
  • 111 Saunders LR, Bankovich AJ, Anderson WC. , et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015; 7 (302) 302ra136
    CrossrefPubMedGoogle Scholar
  • 112 Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol 2019; 12 (01) 61
    CrossrefPubMedGoogle Scholar
  • 113 Tanaka K, Isse K, Fujihira T. , et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer 2018; 115: 116-120
    CrossrefPubMedGoogle Scholar
  • 114 Rudin CM, Pietanza MC, Bauer TM. , et al; SCRX16-001 investigators. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017; 18 (01) 42-51
    CrossrefPubMedGoogle Scholar
  • 115 Byers LA, Wang J, Nilsson MB. , et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2 (09) 798-811
    CrossrefPubMedGoogle Scholar
  • 116 Owonikoko TK, Dahlberg SE, Sica GL. , et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 2019; 37 (03) 222-229
    PubMedGoogle Scholar
  • 117 Thomas A, Vilimas R, Trindade C. , et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: Results from a phase II study. J Thorac Oncol 2019; 14 (08) 1447-1457
    CrossrefPubMedGoogle Scholar